Italy's Chiesi group says that provisional financial results for 2005 marked its third consecutive year of increased turnover as its net sales revenues rose to 565.0 million euros ($672.8 million), 8% higher than in 2004.
Paulo Chiesi, vice president of the Parma-headquartered firm, said that the company's growth had been led by both its R&D program, in which it has invested 71.0 million euros or 12.5% of its turnover during the year, and its range of developmental pipeline products. Mr Chiesi added that the group had completed 10 new Mutual Recognition Procedures and had received around 90 new marketing authorizations for its products, two thirds of which came from European Union regulatory bodies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze